JP Morgan Chase
GALT icon

JP Morgan Chase’s Galectin Therapeutics GALT Stock Holding History

JP Morgan Chase’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,000
Closed -$15K – 5707
2019
Q3 		$15K Hold
4,000
– – ﹤0.01% 5450
2019
Q2 		$16K Buy
+4,000
New +$17.3K ﹤0.01% 5485

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

JP Morgan Chase's GALT Position: Q2 2026 in Review

JP Morgan Chase increased its Galectin Therapeutics (GALT) stake by 237% in Q2 2026, buying an estimated $67.8K and bringing the position to 37,188 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #5662.

JP Morgan Chase first reported a position in GALT in Q1 2014 and has held it in 31 quarters since. The position peaked at $964K in Q1 2019. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • JP Morgan Chase held 37,188 shares of Galectin Therapeutics worth $185K as of Q2 2026.
  • JP Morgan Chase bought 26,145 Galectin Therapeutics shares in Q2 2026, an estimated $67.8K.
  • Galectin Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5662 holding.
  • JP Morgan Chase first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 31 quarters since.
  • JP Morgan Chase's Galectin Therapeutics position peaked at $964K in Q1 2019.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.